DERL1 and urinary bladder cancer: To determine whether Derlin-1 induced drug resistance involves PI3K/AKT activation, we examined whether treatment with the PI3K/AKT inhibitor LY294005 suppressed vialility of Derlin-1-overexpressing bladder cancer cells in response to cisplatin.